Literature DB >> 7541847

Reversion of a Moloney murine leukemia virus RNase H mutant at a second site restores enzyme function and infectivity.

S W Blain1, W A Hendrickson, S P Goff.   

Abstract

The reverse transcriptase of retroviruses contains an RNase H activity essential for the proper synthesis of the viral DNA copy of the RNA genome. We have previously characterized a number of point mutations altering the RNase domain of the Moloney murine leukemia virus reverse transcriptase (S. W. Blain and S. P. Goff, J. Biol. Chem. 268:23585-23592, 1993). One such mutation, Y586F (a Y-to-F change at position 586), reduced RNase H activity, as assayed by in situ gel analysis, to about 5% of the wild-type level and prevented viral replication. We have now recovered a revertant virus with near-normal infectivity and in vitro enzymatic activity. The revertant contains a single substitution, N613H, distant in the primary sequence of the protein, but modeling with the Escherichia coli RNase H structure suggests that the reverted residue is close in space to the original substituted residue. Examination of the structure permits some suggestions as to how this second-site revertant restores enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541847      PMCID: PMC189329     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Effects on DNA synthesis and translocation caused by mutations in the RNase H domain of Moloney murine leukemia virus reverse transcriptase.

Authors:  S W Blain; S P Goff
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

2.  Sequence and spacing requirements of a retrovirus integration site.

Authors:  J Colicelli; S P Goff
Journal:  J Mol Biol       Date:  1988-01-05       Impact factor: 5.469

3.  Domain structure of the Moloney murine leukemia virus reverse transcriptase: mutational analysis and separate expression of the DNA polymerase and RNase H activities.

Authors:  N Tanese; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

4.  RNA-dependent DNA polymerase in virions of Rous sarcoma virus.

Authors:  H M Temin; S Mizutani
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

5.  Enchancement of the infectivity of simian virus 40 deoxyribonucleic acid with diethylaminoethyl-dextran.

Authors:  J H McCutchan; J S Pagano
Journal:  J Natl Cancer Inst       Date:  1968-08       Impact factor: 13.506

6.  Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.

Authors:  S Goff; P Traktman; D Baltimore
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

7.  Identification of the amino acid residues involved in an active site of Escherichia coli ribonuclease H by site-directed mutagenesis.

Authors:  S Kanaya; A Kohara; Y Miura; A Sekiguchi; S Iwai; H Inoue; E Ohtsuka; M Ikehara
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

Review 8.  Ribonuclease H: from discovery to 3D structure.

Authors:  R J Crouch
Journal:  New Biol       Date:  1990-09

9.  Three-dimensional structure of ribonuclease H from E. coli.

Authors:  K Katayanagi; M Miyagawa; M Matsushima; M Ishikawa; S Kanaya; M Ikehara; T Matsuzaki; K Morikawa
Journal:  Nature       Date:  1990-09-20       Impact factor: 49.962

10.  Structure of ribonuclease H phased at 2 A resolution by MAD analysis of the selenomethionyl protein.

Authors:  W Yang; W A Hendrickson; R J Crouch; Y Satow
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

View more
  1 in total

1.  Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.

Authors:  X Li; Y Quan; E J Arts; Z Li; B D Preston; H de Rocquigny; B P Roques; J L Darlix; L Kleiman; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.